FZRQ — Immune Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
HealthcareHighly SpeculativeMicro Cap
2013 December 31st | 2014 December 31st | 2015 December 31st | 2016 December 31st | 2017 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.019 | 0.002 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 2.58 | 16.4 | 16.2 | 27.3 | 16 |
Operating Profit | -2.56 | -16.4 | -16.2 | -27.3 | -16 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -5.75 | -23.6 | -17.2 | -37.5 | -19.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -5.76 | -23.6 | -17.2 | -32.7 | -19.7 |
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -5.76 | -23.6 | -17.2 | -32.7 | -17.9 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -6.69 | -24.4 | -24.1 | -40.6 | -24.8 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -30.7 | -29.2 | -17.7 | -6.64 | -2.02 |